Abstract
Cognitively impaired and spared patient subgroups were identified in psychosis and depression, and in clinical high-risk for psychosis (CHR). Studies suggest differences in underlying brain structural and functional characteristics. It is unclear whether cognitive subgroups are transdiagnostic phenomena in early stages of psychotic and affective disorder which can be validated on the neural level. Patients with recent-onset psychosis (ROP; N = 140; female = 54), recent-onset depression (ROD; N = 130; female = 73), CHR (N = 128; female = 61) and healthy controls (HC; N = 270; female = 165) were recruited through the multi-site study PRONIA. The transdiagnostic sample and individual study groups were clustered into subgroups based on their performance in eight cognitive domains and characterized by gray matter volume (sMRI) and resting-state functional connectivity (rsFC) using support vector machine (SVM) classification. We identified an impaired subgroup (N ROP = 79, N ROD = 30, N CHR = 37) showing cognitive impairment in executive functioning, working memory, processing speed and verbal learning (all p < 0.001). A spared subgroup (N ROP = 61, N ROD = 100, N CHR = 91) performed comparable to HC. Single-disease subgroups indicated that cognitive impairment is stronger pronounced in impaired ROP compared to impaired ROD and CHR. Subgroups in ROP and ROD showed specific symptom- and functioning-patterns. rsFC showed superior accuracy compared to sMRI in differentiating transdiagnostic subgroups from HC (BAC impaired = 58.5%; BAC spared = 61.7%, both: p < 0.01). Cognitive findings were validated in the PRONIA replication sample (N = 409). Individual cognitive subgroups in ROP, ROD and CHR are more informative than transdiagnostic subgroups as they map onto individual cognitive impairment and specific functioning- and symptom-patterns which show limited overlap in sMRI and rsFC. CLINICAL TRIAL REGISTRY NAME: German Clinical Trials Register (DRKS). Clinical trial registry URL: https://www.drks.de/drks_web/ . Clinical trial registry number: DRKS00005042.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Neuropsychopharmacology |
| Jahrgang | 49 |
| Ausgabenummer | 3 |
| Seiten (von - bis) | 573-583 |
| Seitenumfang | 11 |
| ISSN | 0893-133X |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 02.2024 |
Fördermittel
| Träger | Trägernummer |
|---|---|
| Koeln Fortune Program/Faculty of Medicine, University of Cologne | 370/2020 |
| NHMRC-EU | 1075379 |
| National Institute of Mental Health | T32MH122394 |
| Brain and Behavior Research Foundation | 28474 |
| National Alliance for Research on Schizophrenia and Depression | |
| Medical Research Council | |
| National Institute for Health and Care Research | |
| National Health and Medical Research Council | 1105825, 1196508 |
| Rebecca L. Cooper Medical Research Foundation |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 10 – Weniger Ungleichheiten
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
DFG-Fachsystematik
- 2.23-10 Klinische Psychiatrie, Psychotherapie und Kinder- und Jugendpsychiatrie
- 2.23-08 Kognitive und systemische Humanneurowissenschaften
Fingerprint
Untersuchen Sie die Forschungsthemen von „Transdiagnostic subgroups of cognitive impairment in early affective and psychotic illness“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver